Nuvation Bio Inc. (NYSE:NUVB) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Nuvation Bio Inc. (NYSE:NUVB) have earned an average recommendation of “Moderate Buy” from the twelve research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $11.50.

NUVB has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvation Bio in a research report on Thursday, January 22nd. B. Riley Financial assumed coverage on shares of Nuvation Bio in a report on Wednesday, November 19th. They issued a “buy” rating and a $12.00 target price on the stock. Royal Bank Of Canada increased their target price on shares of Nuvation Bio from $9.00 to $12.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. UBS Group began coverage on shares of Nuvation Bio in a research note on Wednesday, January 7th. They issued a “neutral” rating and a $10.00 price objective for the company. Finally, Truist Financial set a $13.00 price objective on Nuvation Bio in a research note on Tuesday, January 27th.

Insider Transactions at Nuvation Bio

In other Nuvation Bio news, insider Dongfang Liu sold 150,000 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $7.82, for a total value of $1,173,000.00. Following the transaction, the insider directly owned 18,000 shares in the company, valued at $140,760. The trade was a 89.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last ninety days, insiders have sold 190,000 shares of company stock worth $1,406,000. Company insiders own 29.93% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Rangeley Capital LLC bought a new position in Nuvation Bio in the 2nd quarter valued at $25,000. Parallel Advisors LLC increased its stake in shares of Nuvation Bio by 51.9% in the third quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock valued at $28,000 after buying an additional 2,597 shares in the last quarter. Cetera Investment Advisers acquired a new stake in shares of Nuvation Bio in the second quarter valued at $29,000. Captrust Financial Advisors acquired a new position in Nuvation Bio during the 2nd quarter worth about $32,000. Finally, Swiss Life Asset Management Ltd acquired a new position in Nuvation Bio during the 3rd quarter worth about $39,000. 61.67% of the stock is owned by institutional investors and hedge funds.

Nuvation Bio Stock Down 0.4%

Shares of NYSE:NUVB opened at $5.77 on Tuesday. The firm has a 50 day simple moving average of $7.24 and a 200 day simple moving average of $5.29. The company has a debt-to-equity ratio of 0.14, a quick ratio of 8.39 and a current ratio of 8.48. Nuvation Bio has a 52 week low of $1.54 and a 52 week high of $9.75. The company has a market cap of $1.98 billion, a PE ratio of -9.01 and a beta of 1.52.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.